Press coverage about OraSure Technologies (NASDAQ:OSUR) has been trending somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OraSure Technologies earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news headlines about the medical instruments supplier an impact score of 46.5614195402814 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
Shares of OraSure Technologies (NASDAQ:OSUR) traded down $0.54 during trading on Monday, reaching $17.46. 973,772 shares of the company’s stock traded hands, compared to its average volume of 738,377. The stock has a market cap of $1,091.67, a P/E ratio of 34.24, a P/E/G ratio of 4.60 and a beta of 1.43. OraSure Technologies has a 52 week low of $10.28 and a 52 week high of $23.01.
OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported $0.12 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.01. The firm had revenue of $52.00 million during the quarter, compared to analysts’ expectations of $50.20 million. OraSure Technologies had a net margin of 18.52% and a return on equity of 13.09%. The business’s revenue for the quarter was up 46.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.13 earnings per share. analysts expect that OraSure Technologies will post 0.31 EPS for the current year.
A number of equities analysts recently weighed in on OSUR shares. Jefferies Group reaffirmed a “buy” rating and set a $23.00 price objective on shares of OraSure Technologies in a research report on Friday, October 20th. Zacks Investment Research upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a report on Wednesday, October 25th. ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. BidaskClub upgraded shares of OraSure Technologies from a “hold” rating to a “buy” rating in a report on Thursday, December 21st. Finally, Canaccord Genuity reiterated a “buy” rating and set a $24.00 price target on shares of OraSure Technologies in a research note on Friday, February 2nd. Two investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $22.25.
TRADEMARK VIOLATION NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact OraSure Technologies (NASDAQ:OSUR) Stock Price” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/12/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-orasure-technologies-osur-share-price.html.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.